Recent Updates
Recently added Catalysts

Pneumococcal conjugate vaccine GSK1024850A

Phase 3

Hepatitis B | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Jan 2, 2020

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment1,437
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00463437Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same VaccinesPHASE3 COMPLETED 1,437Apr 25, 2007Jun 14, 2008Jan 2, 202063 Germany, Poland +1
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Subjects Reporting Fever Above 39.0 Degree Celsius (°C)
During the 4-day (Day 0-3) period after the booster vaccination

Fever was measured as rectal temperature.

Secondary Endpoints
Number of Subjects Reporting Solicited Local Symptoms
During the 4-day (Day 0-3) period after the booster vaccination
Number of Subjects Reporting Solicited General Symptoms
During the 4-day (Day 0-3) period after the booster vaccination
Number of Subjects Reporting Unsolicited Adverse Events (AE)
During the 31-day (Day 0-30) period after the booster vaccination
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™EXPERIMENTALSubjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany \& Poland and Infanrix™ IPV Hib in Spain) and Wyeth's Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™EXPERIMENTALSubjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany \& Poland and Infanrix™ IPV Hib in Spain) and Baxter's Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™EXPERIMENTALSubjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany \& Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
Prevenar™ + Menitorix™ACTIVE_COMPARATORSubjects receiving a booster dose of Wyeth's pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany \& Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
Interventions
NameTypeDescription
Pneumococcal conjugate vaccine GSK1024850ABIOLOGICALIntramuscular injection, 1 dose.
PrevenarBIOLOGICALIntramuscular injection, 1 dose.
Infanrix hexaBIOLOGICALIntramuscular injection, 1 dose. In Germany and Poland.
Infanrix IPV HibBIOLOGICALIntramuscular injection, 1 dose. In Spain.
Infanrix pentaBIOLOGICALIntramuscular injection, 1 dose. In Germany and Poland.
Infanrix IPVBIOLOGICALIntramuscular injection, 1 dose. In Spain.
MeningitecBIOLOGICALIntramuscular injection, 1 dose.
NeisVac-CBIOLOGICALIntramuscular injection, 1 dose.
MenitorixBIOLOGICALIntramuscular injection, 1 dose.
Unlock Study Design Details
Eligibility Criteria
Age Range11 Months — 18 Months
SexALL
Healthy VolunteersYes
Study Sites63

Inclusion Criteria: * Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol. * A male or female between, and including, 11-18 months of age at the time of the booster vaccination. * A male or female who previously participated ...

Countries:GermanyPolandSpain
Unlock Eligibility Criteria